Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
"Our specialized experience in the manufacture of monoclonal antibodiesmakes us an ideal partner to support ARIUS and the manufacturing of theirTrop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President& CEO of Laureate. "As with all of our Life Science client companies, we willwork closely with the ARIUS team to help them achieve their manufacturingobjectives."
Advertisement
"The initiation of manufacturing for our second drug candidatedemonstrates our ability to execute on our milestones and move multiplecandidates from the ARIUS pipeline of drug candidates forward," said Dr. DavidS. Young, President and Chief Executive Officer of ARIUS. "Laureate Pharma hasa track record of expertise in biopharmaceutical manufacturing, includingcapabilities in both clinical and commercial-grade materials and will provideus with a supply of our Trop-2 targeting drug necessary to begin ourpreclinical studies in the first quarter of 2008 in preparation for humanclinical trials."
ARIUS' Trop-2 Signal Transduction Antibody Program has produced the onlyunconjugated antibody currently in development targeting this novel marker.Trop-2 is a protein expressed on the cell-surface and found in many cancerindications including pancreatic, colon, breast and prostate cancer. Thetarget is thought to be a key part of the expansive MAPK pathway. Of morethan 900 abstracts considered for oral presentation at the October 2007 AACR-NCI-EORTC International Conference on Molecular Targets and CancerTherapeutics, the abstract on Trop-2 was one of 12 selected. The Trop-2 SignalTransduction Program was generated using ARIUS' proprietary FunctionFIRST(TM)technology, which selects antibodies based on their ability to kill cancercells.
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development andprotein production company located in Princeton, New Jersey. Laureate Pharmaoffers superior bioprocessing services that accelerate new products fromdevelopment through production. Laureate provides a wide range of specializedservices from process design and development to full-scale cGMP production,purification, aseptic filling, testing, validation, analytical services, andregulatory support. Laureate is focused on two active segments of thebiopharmaceutical industry: monoclonal antibodies and recombinant proteinproducts. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics,Inc. (NYSE: SFE), which provides growth capital for entrepreneurial andinnovative technology and life sciences companies through expansionfinancings, corporate spin-outs, management buyouts, recapitalizations,industry consolidations and early-stage financings. (www.safeguard.com) Formore information, contact Michael Cavanaugh, Vice President Sales, Marketing,and Business Development at (609) 919-3400, or [email protected] orvisit www.laureatepharma.com.
About ARIUS
ARIUS is a biotechnology company discovering and developing the next waveof antibody therapeutics. Established in 1999, ARIUS has built a proprietarytechnology platform, FunctionFIRST(TM) that rapidly identifies and selectsantibodies
